1,000
Participants
Start Date
January 1, 2024
Primary Completion Date
December 31, 2024
Study Completion Date
December 31, 2024
HYBRID
It involves the combination of a sternal sparing left internal mammary artery (LIMA) bypass and percutaneous coronary intervention (PCI) with drug-eluting stents (DES) for non-left anterior descending (LAD) lesions. Through minimally invasive surgical techniques, HCR carries the potential for faster recovery postoperatively, fewer in-hospital complications, and lower utilization of healthcare resources, while providing the key benefits of LIMA-LAD grafting.
University of Roma La Sapienza
OTHER